Drug Type ASO |
Synonyms Alicaforsen, Alicaforsen enema, Alicaforsen sodium (USAN) + [11] |
Target |
Mechanism ICAM-1 inhibitors(Intercellular adhesion molecule-1 inhibitors), Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02811 | Alicaforsen sodium | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pouchitis | NDA/BLA | US | - | |
Pouchitis | NDA/BLA | EU | - | |
Crohn Disease | Phase 3 | US | 10 Jan 2001 | |
Crohn Disease | Phase 3 | CA | 10 Jan 2001 | |
Colitis, Ulcerative | Phase 3 | US | - | |
Colitis, Ulcerative | Phase 3 | EU | - | |
Inflammatory Bowel Diseases | Phase 1 | GB | 16 Mar 2018 |
Phase 3 | 138 | (Alicaforsen) | nrbpxipljl(lgswotypee) = qnukxjyfgp scqhcvjbim (xbvqptqjjy, pvmozukgla - durjykbfah) View more | - | 25 Feb 2020 | ||
Placebo (Placebo) | nrbpxipljl(lgswotypee) = zhfjzqjzig scqhcvjbim (xbvqptqjjy, hktxznhivq - mtsyrltyjv) View more |